{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:18:29Z","timestamp":1790083109179,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04804-8","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:32:22Z","timestamp":1758717142000},"page":"1277-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database"],"prefix":"10.1007","volume":"58","author":[{"given":"Parisa","family":"Aijaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Eby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"4804_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030635","author":"S Sumanasuriya","year":"2018","unstructured":"Sumanasuriya S, De Bono J (2018) Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a030635","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4804_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630589","volume":"11","author":"PJ Vlachostergios","year":"2021","unstructured":"Vlachostergios PJ, Niaz MJ, Sun M, Mosallaie SA, Thomas C, Christos PJ et al (2021) Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol 11:630589","journal-title":"Front Oncol"},{"issue":"9","key":"4804_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C et al (2023) FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 29(9):1651\u20131657","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4804_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103","journal-title":"N Engl J Med"},{"issue":"10276","key":"4804_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804","journal-title":"Lancet"},{"issue":"10459","key":"4804_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN et al (2024) (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404(10459):1227\u20131239","journal-title":"Lancet"},{"issue":"10","key":"4804_CR7","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","volume":"61","author":"A Gafita","year":"2020","unstructured":"Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C et al (2020) Early prostate-specific antigen changes and clinical outcome after (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med 61(10):1476\u20131483","journal-title":"J Nucl Med"},{"issue":"4","key":"4804_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","volume":"87","author":"YH Dai","year":"2025","unstructured":"Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA (2025) A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following Prostate-Specific Membrane Antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer. Eur Urol 87(4):398\u2013408","journal-title":"Eur Urol"},{"key":"4804_CR9","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer: NCCN; 2024 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"1","key":"4804_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM et al (2024) Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol 25(1):99\u2013107","journal-title":"Lancet Oncol"},{"issue":"11","key":"4804_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","volume":"65","author":"V Murthy","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S et al (2024) Efficacy and toxicity of [(177)Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data. J Nucl Med 65(11):1740\u20131744","journal-title":"J Nucl Med"},{"issue":"4","key":"4804_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.34749","volume":"154","author":"E Almuradova","year":"2024","unstructured":"Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S et al (2024) The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer 154(4):692\u2013700","journal-title":"Int J Cancer"},{"issue":"3","key":"4804_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM et al (2024) Real-world outcomes and predictive biomarkers for (177)Lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a European Association of Urology Young Academic Urologists Prostate Cancer Working Group multi-institutional observational study. Eur Urol Oncol 7(3):421\u2013429","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"4804_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.123.266842","volume":"65","author":"A Moradi Tuchayi","year":"2024","unstructured":"Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A et al (2024) Real-world experience with (177)Lu-PSMA-617 radioligand therapy after Food and Drug Administration approval. J Nucl Med 65(5):735\u2013739","journal-title":"J Nucl Med"},{"key":"4804_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A (2021) The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol 98\u201399:30\u201339","journal-title":"Nucl Med Biol"},{"issue":"1","key":"4804_CR16","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu S, Hu W, Chen M, Xiao X, Liu R (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep 14(1):25712","journal-title":"Sci Rep"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04804-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:37:40Z","timestamp":1773844660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04804-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4804"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04804-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}